PIONEER TEENS Trial Reveals Oral Semaglutide Di...

By João L. Carapinha

April 24, 2026

Important results from the PIONEER TEENS phase 3a trial! Oral semaglutide diabetes therapy delivered statistically superior glycemic control compared with placebo in children and adolescents aged 10–17 years with type 2 diabetes. The trial met its...
Terminal Complement Inhibition: Promising Results in IgAN from the I CAN Trial
Advancements in Rare Disease Therapies: CHMP’s April 2026 Insights and ...
Economic Impact of Fragmented Care: Tackling Obesity, Diabetes, and Cardiovas...
Advancements in HIV Two-Drug Regimen: FDA Approves IDVYNSO for Virologically ...
Progress and Challenges in the FDA Accelerated Approval Pathway: A Policy Roa...
Conditional Reimbursement in Chronic Pain Rehabilitation: Navigating Evidence...
Advancing Psychedelic Therapy Access for Treatment-Resistant Mental Illness
Effective Hypertension Control Interventions in Underserved Populations
Null Link Confirmed: Prenatal Acetaminophen Autism Risk Study in Denmark
Amyloid-Beta Treatment Impact: Limited Clinical Benefits and Increased Risks ...
Escalating Public Spending: Semaglutide Off-Label Use Sparks €250 Million Fra...
Advancing B7-H3 Targeted Therapy for Relapsed Extensive-Stage Small Cell Lung...